Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

This cross-sectional study found that frequent use of continuous glucose monitoring (CGM) (greater than 75% sensor wear) was ...

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated ...

Lifecare ASA is a MedTech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) systems for diabetes management. The company focuses on utilizing osmotic ...

Missouri is currently facing a diabetes crisis. Over 598,000 adults — about 10.6% of our state’s population — live with ...

People with cancer who received diabetes care from clinical pharmacists achieved significantly better blood sugar control, ...

Type 2 diabetes (T2D) is a chronic metabolic disorder characterised by insulin resistance and impaired insulin secretion, ...

The "Glucose Goddess" built a brand around her blood sugar balancing hacks. She said a few simple swaps to her diet boosted ...

As people around the world seek ways to manage their diabetes, the continuous glucose monitor (CGM) market continues to grow ...

DexCom Inc. (NASDAQ: DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst ...

Dexcom shares tumbled 12.8% on Friday after executives signaled that the medical device maker's 2026 growth forecast could fall short of Wall Street expectations.mo ...